pozelimab   Click here for help

GtoPdb Ligand ID: 12900

Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
Approved drug Immunopharmacology Ligand
pozelimab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
No information available.
Summary of Clinical Use Click here for help
Pozelimab is in clinical development to determine safety and efficacy in the treament of complement-mediated inflammatory conditions. The FDA approved pozelimab to treat the ultra-rare inflammatory condition, CHAPLE disorder, in August 2023.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04811716 Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy Phase 2 Interventional Regeneron Pharmaceuticals
NCT04209634 Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) Phase 2/Phase 3 Interventional Regeneron Pharmaceuticals
NCT05070858 A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis Phase 3 Interventional Regeneron Pharmaceuticals